nach oben

Erschienen in:

12.11.2019 | Original Article

Helicobacter pylori infection and gastroduodenal lesions in patients with systemic lupus erythematosus

verfasst von: Claudia Mendoza-Pinto, Mario García-Carrasco, Socorro Méndez-Martínez, Tania Mogollán-Delfín, Pamela Munguía-Realpozo, Efrén Herrera-Robles, Ivet Etchegaray-Morales, José Luis Gálvez-Romero, Álvaro Montiel-Jarquín, Aurelio López-Colombo

Erschienen in: Clinical Rheumatology | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Objective

The aim of this study was to determine the frequency of Helicobacter pylori in SLE patients and to compare clinical characteristics and gastroduodenal lesions in patients with and without H. pylori infection.

Methods

Adult SLE patients were selected and subjected to endoscopy. Gastroduodenal lesions were examined by endoscopy and biopsy (antrum and corpus). Biopsies were evaluated by hematoxylin and eosin and Giemsa staining. Immunochromatographic membrane-based assay using amplification was used to test for H. pylori antigen (coproantigen) in stool samples in all participants. Clinical characteristics and gastroduodenal lesions were compared between patients with and without H. pylori infection.

Results

A total of 118 SLE patients were included (mean age 44.7 ± 11.7 years, mean disease duration 11.6 ± 6.0 years), of whom 101 (85.6%) were receiving non-steroidal anti-inflammatory drugs (NSAIDs). The coproantigen test was positive in 32 (27.1%) patients. H. pylori was present in twenty six patients (22.0%) in the gastric biopsy. The frequency of gastric erosions and gastric ulcers were 55.1% and 0.8%, respectively. Gastric erosions were less frequent in SLE patients with H. pylori infection than those without H. pylori (43.5.7% vs. 62.5%; p = 0.04). The age, disease duration, disease activity, chronic damage, gastroprotective drugs, and immunosuppressive therapy did not differ between the two groups.

Conclusions

We found a high frequency of H. pylori infection in SLE patients. The severity of SLE and reception of gastroprotective therapy do not seem to be related to H. pylori infection. Immunosuppressive therapy may not be protective against H. pylori infection in SLE patients.

Key Points

• In patients with systemic lupus erythematosus (SLE), the frequency of Helicobacter pylori infection was 39% and gastric erosions were frequent.

• Disease activity, chronic damage, gastroprotective drugs, and immunosuppressive therapy may not affect the prevalence of H. pylori infection in SLE patients.

Marshall BJ, Armstrong JA, McGechie DB, Glancy RJ (1985) Attempt to fulfil Koch’s postulates for pyloric Campylobacter. Med J Aust 142:436–439CrossRef

Chan FK, Sung JJ, Chung SC et al (1997) Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet (London, England) 350:975–979CrossRef

Taha AS, Dahill S, Morran C, Hudson N, Hawkey CJ, Lee FD, Sturrock RD, Russell RI (1999) Neutrophils, Helicobacter pylori, and nonsteroidal anti-inflammatory drug ulcers. Gastroenterology 116:254–258CrossRef

Voutilainen M, Sokka T, Juhola M, Farkkilä M, Hannonen P (1998) Nonsteroidal anti-inflammatory drug-associated upper gastrointestinal lesions in rheumatoid arthritis patients. Relationships to gastric histology, Helicobacter pylori infection, and other risk factors for peptic ulcer. Scand J Gastroenterol 33:811–816PubMed

Veijola L, Myllyluoma E, Korpela R, Rautelin H (2005) Stool antigen tests in the diagnosis of Helicobacter pylori infection before and after eradication therapy. World J Gastroenterol 11:7340–7344CrossRef

Andrews J, Marsden B, Brown D, Wong VS, Wood E, Kelsey M (2003) Comparison of three stool antigen tests for Helicobacter pylori detection. J Clin Pathol 56:769–771CrossRef

Wallace DJ, Metzger AL, Klinenberg JR (1989) NSAID usage patterns by rheumatologists in the treatment of SLE. J Rheumatol 16:557–560PubMed

Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, Aydintug AO, Jedryka-Góral A, de Ramón E, Fernández-Nebro A, Galeazzi M, Haga HJ, Mathieu A, Houssiau F, Ruiz-Irastorza G, Ingelmo M, Hughes GR (1999) Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 78:167–175CrossRef

Reshetnyak TM, Doroshkevich IA, Seredavkina NV, Nasonov EL, Maev IV, Reshetnyak VI (2019) The contribution of drugs and Helicobacter pylori to gastric mucosa changes in patients with systemic lupus erythematosus and antiphospholipid syndrome. Int J Rheumatol 2019:9698086. https://doi.org/10.1155/2019/9698086 CrossRefPubMedPubMedCentral

10.

Luo J-C, Chang F-Y, Chen T-S, Ng YY, Lin HC, Lu CL, Chen CY, Lin HY, Lee SD (2009) Gastric mucosal injury in systemic lupus erythematosus patients receiving pulse methylprednisolone therapy. Br J Clin Pharmacol 68:252–259. https://doi.org/10.1111/j.1365-2125.2009.03445.x CrossRefPubMedPubMedCentral

11.

Tan EM, Cohen AS, Fries JF, Masi AT, McShane D, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277CrossRef

12.

Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725. https://doi.org/10.1002/art.1780400928 CrossRef

13.

Drossman DA (2006) The functional gastrointestinal disorders and the Rome III process. Gastroenterology 130:1377–1390. https://doi.org/10.1053/j.gastro.2006.03.008 CrossRefPubMed

14.

Gladman DD, Ibanez D, Urowitz MB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29:288–291

15.

Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, Bacon P, Bombardieri S, Hanly J, Hay E, Isenberg D, Jones J, Kalunian K, Maddison P, Nived O, Petri M, Richter M, Sanchez-Guerrero J, Snaith M, Sturfelt G, Symmons D, Zoma A (1996) The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 39:363–369CrossRef

16.

Kazemi S, Tavakkoli H, Habizadeh MR, Emami MH (2011) Diagnostic values of Helicobacter pylori diagnostic tests: stool antigen test, urea breath test, rapid urease test, serology and histology. J Res Med Sci 16:1097–1104PubMedPubMedCentral

17.

Dixon MF, Genta RM, Yardley JH, Correa P (1996) Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 20:1161–1181CrossRef

18.

Lee JY, Kim N (2015) Diagnosis of Helicobacter pylori by invasive test: histology. Ann Transl Med 3:10. https://doi.org/10.3978/j.issn.2305-5839.2014.11.03 CrossRefPubMedPubMedCentral

19.

Watanabe Y, Ozasa K, Higashi A et al (1997) Helicobacter pylori infection and atrophic gastritis. A case-control study in a rural town of Japan. J Clin Gastroenterol 25:391–394CrossRef

20.

Torres J, Leal-Herrera Y, Perez-Perez G, Gomez A, Camorlinga-Ponce M, Cedillo-Rivera R, Tapia-Conyer R, Muñoz O (1998) A community-based seroepidemiologic study of Helicobacter pylori infection in Mexico. J Infect Dis 178:1089–1094CrossRef

21.

Kalabay L, Fekete B, Czirjak L et al (2002) Helicobacter pylori infection in connective tissue disorders is associated with high levels of antibodies to mycobacterial hsp65 but not to human hsp60. Helicobacter 7:250–256CrossRef

22.

Showji Y, Nozawa R, Sato K, Suzuki H (1996) Seroprevalence of Helicobacter pylori infection in patients with connective tissue diseases. Microbiol Immunol 40:499–503CrossRef

23.

Camargo MC, Lazcano-Ponce E, Torres J, Velasco-Mondragon E, Quiterio M, Correa P (2004) Determinants of Helicobacter pylori seroprevalence in Mexican adolescents. Helicobacter 9:106–114. https://doi.org/10.1111/j.1083-4389.2004.00206.x CrossRefPubMed

24.

Labenz J, Tillenburg B, Peitz U et al (1996) Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology 110:725–732CrossRef

25.

Seriolo B, Cutolo M, Zentilin P, Savarino V (2001) Helicobacter pylori infection in rheumatoid arthritis. J Rheumatol 28:1195–1196PubMed

26.

Ishikawa N, Fuchigami T, Matsumoto T, Kobayashi H, Sakai Y, Tabata H, Takubo N, Yamamoto S, Nakanishi M, Tomioka K, Fujishima M (2002) Helicobacter pylori infection in rheumatoid arthritis: effect of drugs on prevalence and correlation with gastroduodenal lesions. Rheumatology (Oxford) 41:72–77CrossRef

27.

Iwai H, Nakamichi N, Nakae K, Konishi M, Inaba M, Hoshino S, Baba S, Amakawa R (2009) Parotid mucosa-associated lymphoid tissue lymphoma regression after Helicobacter pylori eradication. Laryngoscope 119:1491–1494. https://doi.org/10.1002/lary.20258 CrossRefPubMed

28.

Radic M, Kaliterna DM, Bonacin D et al (2013) Is Helicobacter pylori infection a risk factor for disease severity in systemic sclerosis? Rheumatol Int 33:2943–2948. https://doi.org/10.1007/s00296-012-2585-z CrossRefPubMed

29.

Gasbarrini A, Franceschi F, Tartaglione R et al (1998) Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Lancet (London, England) 352:878. https://doi.org/10.1016/S0140-6736(05)60004-9 CrossRef

30.

Tatti S, Suzuki V, Fleider L, Maldonado V, Caruso R, Tinnirello Mde L (2012) Anal intraepithelial lesions in women with human papillomavirus-related disease. J Low Genit Tract Dis 16:454–459. https://doi.org/10.1097/LGT.0b013e31825d2d7a CrossRefPubMed

31.

Mizokami Y, Tamura K, Fukuda Y et al (1994) Non-steroidal anti-inflammatory drugs associated with gastroduodenal injury and Helicobacter pylori. Eur J Gastroenterol Hepatol 6(Suppl 1):S109–S112PubMed

32.

Taha AS, Sturrock RD, Russell RI (1992) Helicobacter pylori and peptic ulcers in rheumatoid arthritis patients receiving gold, sulfasalazine, and nonsteroidal anti-inflammatory drugs. Am J Gastroenterol 87:1732–1735PubMed

33.

El-Omar E, Penman I, Cruikshank G et al (1994) Low prevalence of Helicobacter pylori in inflammatory bowel disease: association with sulphasalazine. Gut 35:1385–1388CrossRef

34.

Moriyama T, Matsumoto T, Fuchigami T et al (2004) Changes in Helicobacter pylori status in patients with rheumatoid arthritis under non-steroidal anti-inflammatory drugs. Scand J Gastroenterol 39:111–118CrossRef

Titel: Helicobacter pylori infection and gastroduodenal lesions in patients with systemic lupus erythematosus
verfasst von: Claudia Mendoza-Pinto
Mario García-Carrasco
Socorro Méndez-Martínez
Tania Mogollán-Delfín
Pamela Munguía-Realpozo
Efrén Herrera-Robles
Ivet Etchegaray-Morales
José Luis Gálvez-Romero
Álvaro Montiel-Jarquín
Aurelio López-Colombo
Publikationsdatum: 12.11.2019
Verlag: Springer London
Erschienen in: Clinical Rheumatology / Ausgabe 2/2020
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-019-04805-w

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Objective

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2020

Comment on “Impact of TNF-Α inhibitor on lipid profile and atherogenic index of plasma in axial spondyloarthritis: 2-year follow-up data from the catholic axial spondyloarthritis cohort (CASCO)”

Response to “Comment on ‘Impact of TNF-α inhibitor on lipid profile and atherogenic index of plasma in axial spondyloarthritis: Two-year follow-up data from the Catholic Axial Spondyloarthritis COhort (CASCO)’”

Efficacy and safety of iguratimod on patients with relapsed or refractory IgG4-related disease

Stand-alone renal SLICC criterion with full house glomerular deposits: is it enough for childhood lupus nephritis?

Infectious profile in inpatients with ANCA-associated vasculitis: a single-center retrospective study from Southern China